Unknown (Motor Neuron Disease)

The designation 'Unknown for motor neuron disease' refers to the significant proportion of motor neuron disease (MND) cases, including approximately 90% of Amyotrophic Lateral Sclerosis (ALS) instances, for which no specific molecular target or primary cause has been identified [1, 2, 4]. While genetic mutations in proteins such as SOD1, C9orf72, and TDP-43 account for familial forms, the majority of sporadic cases lack a clear therapeutic target [14, 19]. Currently approved treatments like riluzole and edaravone are used to manage the condition, yet their precise biochemical targets in the human central nervous system remain largely unknown or are characterized by broad, multi-modal effects [7, 13]. Riluzole is generally associated with the inhibition of glutamate release and sodium channel blockade, while edaravone is recognized for its antioxidant properties in reducing oxidative stress [9, 15]. The absence of a well-defined molecular target poses a substantial challenge for drug discovery, as it necessitates the use of phenotypic screening and the identification of downstream biomarkers like neurofilament light chain to monitor disease progression [12, 20]. Consequently, 'Unknown' in this context highlights a critical gap in the understanding of MND pathophysiology and the urgent need for research into novel disease-modifying targets.

Other names

Unknown targetUnidentified targetUnknown etiology

The mechanisms of action for drugs used in motor neuron disease where the specific target is unknown include glutamate neurotransmission modulation and antioxidant activity.